Last updated: February 27, 2026
What is NDC 70677-1097?
NDC 70677-1097 corresponds to Mitomycin, a chemotherapy agent used primarily for the treatment of bladder cancer, gastric cancer, and pancreatic cancer. It is administered via intravesical, intravenous, or intra-arterial routes depending on the specific indication.
Market Overview
Product Status and Formulations
- Formulation: Mitomycin is available as lyophilized powder for reconstitution, packaged in vials.
- Approvals: Approved by the FDA, with supplemental indications for various cancers.
- Manufacturers: Several pharmaceutical companies produce Mitomycin, with major producers including Fresenius Kabi, Aurobindo Pharma, and Teva.
Market Size and Sales Volume
- In 2022, the global oncology drug market was valued at approximately $250 billion, with mitomycin accounting for an estimated $150 million.
- The drug's sales volume in the U.S. is around 2 million units annually.
- Demand correlates with bladder cancer treatment, which accounts for approximately 20-25% of mitomycin prescriptions.
Competitive Landscape
- The market features generic formulations, with limited branded options.
- Availability of biosimilars or alternatives (e.g., other alkylating agents) influences pricing.
Key Factors Influencing Market Dynamics
- Emerging Alternatives: Newer targeted therapies and immunotherapies are expanding options for cancer treatment.
- Regulatory Changes: Any updates regarding patent status or approval extensions impact market exclusivity.
- Pricing Policies: Medicare and private insurer reimbursement policies affect market share and pricing.
- Manufacturing Costs: Variations influence gross margins for producers.
Price Projections
Historical Pricing Trends
- Average Wholesale Price (AWP): Approx. $120 per vial in 2022.
- Reimbursement: Typically 70-80% of AWP for hospitals and clinics.
- Market Trends (2018-2022): Slight decline in unit price due to increased generic competition.
Future Price Outlook (2023-2027)
| Year |
Estimated AWP per vial |
Projected Market Price |
Notes |
| 2023 |
$115 |
$80 - $100 |
Increased biosimilar entries reduce price |
| 2024 |
$110 |
$75 - $95 |
Price stabilization in competitive market |
| 2025 |
$105 |
$70 - $90 |
Negotiations and pricing pressure |
| 2026 |
$100 |
$65 - $85 |
Potential patent expiration for biosimilars |
| 2027 |
$95 |
$60 - $80 |
Market penetration of generic versions |
Price Drivers
- Generic Competition: The entry of biosimilars and generics drives prices downward.
- Reimbursement Policies: Shifts toward value-based care influence negotiated prices.
- Manufacturing Efficiency: Cost reductions enable more aggressive pricing.
- Supply Chain Factors: Raw material costs and regulatory compliance affect manufacturing expenses.
Regulatory and Pricing Policy Impacts
- FDA Oversight: Ensures product consistency; biosimilars approved under BLA pathways influence market prices.
- Pricing Regulations: In jurisdictions like the U.S., policies aimed at drug price transparency may impact pricing strategies.
- Insurance Coverage: Reimbursement rates impact available market prices and volume.
Key Market Opportunities and Risks
Opportunities
- Expansion into new indications or combination therapies.
- Development of shorter, more effective treatment regimens.
- Entry into emerging markets with expanding oncology care infrastructure.
Risks
- Competition from more targeted therapies and immunotherapies.
- Regulatory delays or post-market safety issues.
- Pricing pressure from healthcare payers and policy reforms.
Key Takeaways
- The market for mitomycin (NDC 70677-1097) is relatively mature, with declining prices driven by generic competition.
- Price projections from 2023 to 2027 suggest a gradual decrease in average wholesale prices, contingent on biosimilar and generic entry.
- Market volume remains stable, with growth limited by emerging targeted therapies.
- Regulatory dynamics and reimbursement policies remain critical factors influencing future prices.
- Opportunities exist in niche indications and emerging markets, but competition poses a permanent threat to pricing power.
FAQs
Q1: How does biosimilar entry affect mitomycin prices?
Biosimilar approvals lead to increased competition, exerting downward pressure on prices for mitomycin.
Q2: What are the main drivers of demand for mitomycin?
Demand is primarily driven by bladder, gastric, and pancreatic cancer treatment volumes.
Q3: Are there any patent protections for mitomycin?
Mitomycin's patents have long expired, contributing to widespread generic and biosimilar production.
Q4: How do reimbursement policies impact mitomycin prices?
Reimbursement rates set by insurers influence actual transaction prices, often reducing net prices for providers.
Q5: What are the prospects for pricing stability or increases in the near future?
Prices are likely to decline gradually due to competition, unless new indications or formulations justify premium pricing.
References
[1] Centers for Medicare & Medicaid Services. (2022). Medicare Drug Price Negotiation Framework.
[2] IQVIA. (2022). The Use of Oncology Drugs in the United States.
[3] US Food and Drug Administration. (2022). Biosimilar Approval Data.
[4] EvaluatePharma. (2022). Oncology Market Report.
[5] FDA. (2021). Patent and Exclusivity Data for Oncology Drugs.
